Comparison of adverse events associated with different spacers used with non-extrafine beclometasone dipropionate for asthma
Open Access
- 8 February 2019
- journal article
- research article
- Published by Springer Nature in npj Primary Care Respiratory Medicine
- Vol. 29 (1) , 1-8
Abstract
Co-prescription of Aerochamber® spacer with non-extrafine beclometasone diproprionate (non-EF BDP) is common but unlicensed. We report a comparison of inhaled corticosteroid (ICS)-related adverse events between patients co-prescribed Aerochamber compared to the licensed Volumatic® spacer. We utilised two historical cohorts: questionnaire-based and electronic medical record (EMR)-based, to assess patient-reported and EMR-recorded adverse events in patients with asthma prescribed non-EF BDP. Marginal effect estimate (MEE) was calculated to determine non-inferiority of Aerochamber compared to Volumatic in terms of patient-reported oral thrush and hoarseness with margin of 0.13. Other patient-reported adverse events (sore throat, bruising, weight gain, and coughing), and EMR-recorded adverse events were also assessed. Rate of patient-reported oral adverse events were non-inferior in 385 patients prescribed Aerochamber compared to 155 patients prescribed Volumatic (27.7 vs 29.9%; MEE, −0.043; 95% CI, −0.133 to 0.047). Total patient-reported adverse events did not differ significantly between Aerochamber and Volumatic (53.3 vs 49.7% with ≥1 adverse event). The EMR-based study of 1471 matched pairs of subjects did not show significantly different number of EMR-recorded adverse events between Aerochamber and Volumatic (12.5 vs 12.8% with ≥1 adverse events). Co-prescribing Aerochamber with non-EF BDP does not increase the risk for patient-reported and EMR-recorded ICS-related adverse events compared to co-prescribing Volumatic.Keywords
Funding Information
- Chiesi Limited
This publication has 42 references indexed in Scilit:
- Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherenceJournal of Allergy and Clinical Immunology, 2011
- What the pulmonary specialist should know about the new inhalation therapiesEuropean Respiratory Journal, 2011
- Local oropharyngeal side effects of inhaled corticosteroids in patients with asthmaAllergy, 2006
- Comparison of the Oropharyngeal Deposition of Inhaled Ciclesonide and Fluticasone Propionate in Patients With AsthmaThe Journal of Clinical Pharmacology, 2005
- The expression of aversion to medicines in general practice consultationsSocial Science & Medicine, 2004
- Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasoneAnnals of Allergy, Asthma & Immunology, 2003
- A comparative analysis of the particle size output of beclomethasone diproprionate, salmeterol xinafoate and fluticasone propionate metered dose inhalers used with the Babyhaler, Volumatic and Aerochamber spacer devicesBritish Journal of Clinical Pharmacology, 1999
- Twice daily beclomethasone dipropionate administered with a concentrated aerosol inhaler: efficacy and patient compliance.Thorax, 1986
- Inhaled beclomethasone and oral candidiasis.Archives of Disease in Childhood, 1986
- Design and characteristics of a portable breath actuated, particle size selective medical aerosol inhalerJournal of Aerosol Science, 1982